Neuromyelitis optica spectrum disorder - ravulizumab - initial authority application form (PB382)

Use this form to apply for initial PBS-subsidised treatment with ravulizumab for neuromyelitis optica spectrum disorder.

Page last updated: 1 April 2025.
QC 81036